Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | BTK M437R |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| BTK M437R | diffuse large B-cell lymphoma | resistant | Pirtobrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK M437R demonstrated resistance to Jaypirca (pirtobrutinib) in culture (PMID: 35196427). | 35196427 | |
| BTK M437R | chronic lymphocytic leukemia | predicted - resistant | Pirtobrutinib | Case Reports/Case Series | Actionable | In a clinical case study, a patient with chronic lymphocytic leukemia harboring BTK C481S who previously responded to Jaypirca (pirtobrutinib) treatment was found to have acquired BTK M437R upon disease progression (PMID: 35196427). | 35196427 | |
| BTK M437R | diffuse large B-cell lymphoma | sensitive | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, Imbruvica (ibrutinib) treatment inhibited phosphorylation of Btk and decreased viability of a diffuse large B-cell lymphoma cell line expressing BTK M437R in culture (PMID: 35196427). | 35196427 | |
| BTK M437R | diffuse large B-cell lymphoma | resistant | Fenebrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, a diffuse large B-cell lymphoma cell line expressing BTK M437R demonstrated resistance to Fenebrutinib (GDC-0853) in culture (PMID: 35196427). | 35196427 | |
| BTK M437R | diffuse large B-cell lymphoma | sensitive | ARQ 531 | Preclinical - Cell culture | Actionable | In a preclinical study, ARQ 531 treatment inhibited viability of a diffuse large B-cell lymphoma cell line harboring BTK M437R in culture (PMID: 35196427). | 35196427 | |
| BTK M437R | lymphoma | predicted - sensitive | DZD8586 | Preclinical - Cell culture | Actionable | In a preclinical study, DZD8586 inhibited proliferation of lymphoma cells expressing BTK M437R in culture (Blood (2023) 142 (Supplement 1): 2822). | detail... |